Starting in a bioscientist position at Anglo-Swedish drugs group AstraZeneca after graduating from Southampton University, Gladys Nunez found her home at Amgen two years later when she joined the firm as a biochemist in 1997.
In 2002, Nunez joined the company’s business development unit, and has completed numerous deals for the company over the past 13 years, focused on discovery, development, and commercial applications in life sciences. She also managed Amgen’s Academic Alliance Group, an initiative to build bridges between academia and industry through the establishment of comprehensive academic alliances, for two years from 2008 before becoming a principal at Amgen Ventures at the end of 2014.
She said on her updated LinkedIn profile: “One of my focus areas is also working closely with Amgen’s digital health organisation which has been established over the past two years supporting alliances with key digital health venture groups and organisations.”
Since moving, Nunez has helped judge PathoVax’s innovation RGVax technology as the top winner at Harvard’s Healthcare Innovation and Commercialisation workshop.
For more than a decade, Amgen Ventures has invested in more than 30 emerging biotechnology companies to advance promising medicines and technologies.